EP1572724A4 - Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy - Google Patents

Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy

Info

Publication number
EP1572724A4
EP1572724A4 EP03711418A EP03711418A EP1572724A4 EP 1572724 A4 EP1572724 A4 EP 1572724A4 EP 03711418 A EP03711418 A EP 03711418A EP 03711418 A EP03711418 A EP 03711418A EP 1572724 A4 EP1572724 A4 EP 1572724A4
Authority
EP
European Patent Office
Prior art keywords
kdr
vegf
diagnosis
therapy
use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03711418A
Other languages
German (de)
French (fr)
Other versions
EP1572724A2 (en
Inventor
Aaron K Sato
Daniel J Sexton
Robert C Ladner
Daniel T Dransfield
Rolf E Swenson
Edmund R Marinelli
Kondareddiar Ramalingam
Adrian D Nunn
Wronski Mathew A Von
Ajay Shrivastava
Sibylle Pochon
Philippe Bussat
Christophe Arbogast
Radhakrishna Pillai
Hong Fan
Karen E Linder
Bo Song
Palaniappa Nanjappan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco International BV
Dyax Corp
Original Assignee
Bracco International BV
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US36085102P priority Critical
Priority to US360851P priority
Priority to US44041103P priority
Priority to US440411P priority
Application filed by Bracco International BV, Dyax Corp filed Critical Bracco International BV
Priority to PCT/US2003/006731 priority patent/WO2003074005A2/en
Publication of EP1572724A2 publication Critical patent/EP1572724A2/en
Publication of EP1572724A4 publication Critical patent/EP1572724A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/22Echographic preparations; Ultrasound imaging preparation Optoacoustic imaging preparations
    • A61K49/222Echographic preparations; Ultrasound imaging preparation Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids, proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/50Chemical or biological analysis of biological material for identifying the disease, e.g. blood or urine testing, rapid diagnostic tests [RTDs] or immunological testing
    • Y02A50/58Chemical or biological analysis of biological material for identifying the disease, e.g. blood or urine testing, rapid diagnostic tests [RTDs] or immunological testing the disease being Malaria
EP03711418A 2002-03-01 2003-03-03 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy Withdrawn EP1572724A4 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US36085102P true 2002-03-01 2002-03-01
US360851P 2002-03-01
US44041103P true 2003-01-15 2003-01-15
US440411P 2003-01-15
PCT/US2003/006731 WO2003074005A2 (en) 2002-03-01 2003-03-03 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10185498.2A EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis
EP08008365A EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10185498.2A Division EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis
EP08008365A Division EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Publications (2)

Publication Number Publication Date
EP1572724A2 EP1572724A2 (en) 2005-09-14
EP1572724A4 true EP1572724A4 (en) 2007-03-14

Family

ID=27791656

Family Applications (3)

Application Number Title Priority Date Filing Date
EP03711418A Withdrawn EP1572724A4 (en) 2002-03-01 2003-03-03 Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
EP08008365A Active EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP10185498.2A Active EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP08008365A Active EP2014310B8 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
EP10185498.2A Active EP2301587B1 (en) 2002-03-01 2003-03-03 KDR and VEGF/KDR binding peptides and their use in diagnosis

Country Status (7)

Country Link
EP (3) EP1572724A4 (en)
JP (2) JP2006514915A (en)
AU (2) AU2003213730A1 (en)
CA (2) CA2666005C (en)
ES (2) ES2506142T3 (en)
SI (1) SI2301587T1 (en)
WO (1) WO2003074005A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
CA2477935C (en) * 2002-03-01 2015-01-06 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
WO2004065621A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7666979B2 (en) * 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
NO20026286D0 (en) * 2002-12-30 2002-12-30 Amersham Health As new peptides
KR101076053B1 (en) 2003-02-04 2011-10-21 브라코 인터내셔날 비.브이. Ultrasound contrast agents and process for the preparation thereof
RU2361876C2 (en) * 2003-04-22 2009-07-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик С.А.С. Peptide vectors
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
DE602005010424D1 (en) 2004-06-03 2008-11-27 Bracco Research Sa Liposomal arrangement for therapeutic and / or diagnostic application
AU2005273865B2 (en) 2004-08-18 2011-02-24 Bracco Suisse S.A. Gas-filled microvesicles composition for contrast imaging
EP1846015A4 (en) * 2005-01-19 2009-08-12 Mathew Mark Zuckerman Method, compositions and classification for tumor diagnostics and treatment
EP1714642A1 (en) 2005-04-18 2006-10-25 Bracco Research S.A. Pharmaceutical composition comprising gas-filled microcapsules for ultrasound mediated delivery
EP2359864B1 (en) * 2005-12-09 2019-04-17 Bracco Suisse SA Targeting Vector-Phospholipid Conjugates
WO2008028917A1 (en) 2006-09-05 2008-03-13 Bracco Research Sa Gas-filled microvesicles with polymer-modified lipids
US8293214B2 (en) 2006-12-19 2012-10-23 Bracco Suisse S.A. Targeting and therapeutic compounds and gas-filled microvesicles comprising said compounds
AU2009301141B2 (en) 2008-10-07 2015-08-27 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
WO2011046991A2 (en) * 2009-10-15 2011-04-21 Gilead Connecticut, Inc. Certain substituted ureas as modulators of kinase activity
JP6313329B2 (en) 2012-12-21 2018-04-18 ブラッコ・スイス・ソシエテ・アノニムBracco Suisse SA Gas filled micro vesicle
EP3185912A1 (en) * 2014-08-29 2017-07-05 Anmi S.A. Mono-, di- or polysaccharide used as metal inhibitor in the preparation of 68ga-chelate-functionalized targeting agent
US20180161462A1 (en) * 2015-06-10 2018-06-14 Teikyo University Theranostic bubble preparation (tb), and method for using same
TR201723077A2 (en) * 2017-12-29 2019-07-22 Ege Ueniversitesi Ultrasound sensitive magnetic nanoparticles targeted drug carrier system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063380A1 (en) * 1999-04-16 2000-10-26 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
WO2001052875A1 (en) * 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
WO2002016412A2 (en) * 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4391797A (en) 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
DE3313946A1 (en) 1983-04-15 1984-10-18 Schering Ag Microparticles and gasblaeschen-containing ultrasound contrast agents
DE3313947A1 (en) 1983-04-15 1984-10-18 Schering Ag Microparticles and gasblaeschen-containing ultrasound contrast agents
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
MX174467B (en) 1986-01-23 1994-05-17 Squibb & Sons Inc decane 1,4,7-triscarboxymethyl-1,4,7,10-tetraazaciclodo substituted compounds 1 and Analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
DE3726264A1 (en) 1987-08-07 1989-02-16 Bayer Ag Method for the production of moisture-hardening binder compounds and their use
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE3834705A1 (en) 1988-10-07 1990-04-12 Schering Ag microparticles ultrasound contrast agents from gasblaeschen and fatty acid-containing
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5118797A (en) 1989-08-28 1992-06-02 E. R. Squibb & Sons, Inc. Rhenium tris dioxime complexes
CA2065290C (en) 1989-08-28 2000-12-12 Randall B. Lauffer Hydroxy-aryl metal chelates for diagnostic nmr imaging
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
CA2034042C (en) 1990-01-18 1999-08-17 Adrian D. Nunn Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
IN172208B (en) 1990-04-02 1993-05-01 Sint Sa A method of preparing a composition adapted for injection into the blood stream and body cavities of living beings
US5183653A (en) 1990-04-13 1993-02-02 E. R. Squibb & Sons, Inc. Boronic acid adducts of metal dioxime complexes useful in labelling proteins and other amine-containing compounds
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5849261A (en) 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
DE69230525T2 (en) 1991-02-08 2000-06-21 Diatide Inc Technetium-99m labeled polypeptides for image forming
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
DK0586524T3 (en) 1991-06-03 1997-05-20 Nycomed Imaging As
AT151993T (en) 1991-07-05 1997-05-15 Nycomed Imaging As Improvements to contrast agents
US5808091A (en) 1991-10-29 1998-09-15 Bracco International B.V. Rhenium and technetium complexes containing a hypoxia localizing moiety
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
HUT74827A (en) 1993-07-02 1997-02-28 Molecular Biosystems Inc Protein encapsulated insoluble gas microspheres and their preparation and use as ultrasonic imaging agents
JPH09500140A (en) 1993-07-19 1997-01-07 レゾリューション・ファーマスーティカルズ・インコーポレーテッド N ▲ under 3 ▼ s hydrazino type radionuclide chelating agent having a configuration
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5574140A (en) 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
EP0682530B1 (en) 1993-12-15 2003-03-19 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
JP2891647B2 (en) 1994-03-11 1999-05-17 株式会社日本触媒 Organic sulfide compound and a method of manufacturing the same
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US5582814A (en) 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
CA2188292A1 (en) 1994-04-20 1995-11-02 Larry Margerum Contrast agents
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5662885A (en) 1994-07-22 1997-09-02 Resolution Pharmaceuticals Inc. Peptide derived radionuclide chelators
GB9417941D0 (en) 1994-09-06 1994-10-26 Nycomed Imaging As Improvements in or relating to contrast agents
US5556939A (en) 1994-10-13 1996-09-17 Merck Frosst Canada, Inc. TC or RE radionuclide labelled chelate, hexapeptide complexes useful for diagnostic or therapeutic applications
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst A method for in vivo diagnostics by means of NIR-radiation
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
TW319763B (en) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US5837680A (en) 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
KR100500334B1 (en) 1996-02-19 2005-09-09 아머샴 헬스 에이에스 Improvements in or Relating to Contrast Agents
CA2247620A1 (en) 1996-04-01 1997-10-09 Epix Medical, Inc. Bioactivated diagnostic imaging contrast agents
MXPA99001053A (en) 1996-08-02 2002-03-11 Nycomed Imaging As Improvements in or relating to contrast agents.
AT238073T (en) 1996-10-21 2003-05-15 Amersham Health As Improvements to, or relating to contrast agents in ultrasound image representation
EP0991427A2 (en) 1996-10-28 2000-04-12 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
WO1998018501A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
ES2206689T3 (en) 1996-10-28 2004-05-16 Amersham Health As Contrast agents.
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
EP0963209A2 (en) 1996-10-28 1999-12-15 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
US5919967A (en) 1997-04-11 1999-07-06 Epix Medical, Inc. Process for synthesizing phosphodiesters
DE19717904A1 (en) 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid labile and enzymatically cleavable dye constructs for diagnosis with near-infrared light and for therapy
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion Transdermal delivery system
GB9712525D0 (en) 1997-06-16 1997-08-20 Nycomed Imaging As Method
IL134985D0 (en) 1997-10-02 2001-05-20 Epix Medical Inc A method for contrast enhanced diagnostic imaging
US6165458A (en) 1997-12-26 2000-12-26 Pharmaderm Laboratories Ltd. Composition and method for dermal and transdermal administration of a cytokine
DE69925461T2 (en) 1998-02-09 2006-04-27 Bracco International B.V. Targeted distribution of biological-active media
BR9909420A (en) * 1998-03-31 2001-09-25 Du Pont Pharm Co Compound, kit, composition metalofarmacêutica diagnostic or therapeutic composition ultrasound contrast agent, therapeutic radiopharmaceutical composition and diagnostic composition radiopharmaceutical
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
CA2361553A1 (en) * 1999-01-29 2000-08-03 Zhenping Zhu Antibodies specific to kdr and uses thereof
US6294525B1 (en) 1999-09-01 2001-09-25 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
EP1289565B1 (en) 2000-06-02 2015-04-22 Bracco Suisse SA Compounds for targeting endothelial cells
EP1311302A2 (en) * 2000-06-21 2003-05-21 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000063380A1 (en) * 1999-04-16 2000-10-26 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
WO2001052875A1 (en) * 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
WO2002016412A2 (en) * 2000-08-18 2002-02-28 Dyax Corp. Binding polypeptides for b lymphocyte stimulator protein (blys)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BINETRUY-TOURNAIRE ROSELYNE ET AL: "Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 7, 3 April 2000 (2000-04-03), pages 1525 - 1533, XP002179245, ISSN: 0261-4189 *
FAIRBROTHER W J ET AL: "NOVEL PEPTIDES SELECTED TO BIND VASCULAR ENDOTHELIAL GROWTH FACTOR TARGET THE RECEPTOR-BINDING SITE", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 37, no. 51, 22 December 1998 (1998-12-22), pages 17754 - 17764, XP000876734, ISSN: 0006-2960 *
HAIYAN JIA ET AL: "PEPTIDES ENCODED BY EXON 6 OF VEGF INHIBIT ENDOTHELIAL CELL BIOLOGICAL RESPONSES AND ANGIOGENESIS INDUCED BY VEGF", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 283, no. 1, 2001, pages 164 - 173, XP002941058, ISSN: 0006-291X *
IWAMOTO Y ET AL: "YIGSR, A SYNTHETIC LAMININ PENTAPEPTIDE, INHIBITS EXPERIMENTAL METASTATIS FORMATION", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 238, no. 4830, 20 November 1987 (1987-11-20), pages 1132 - 1134, XP001135169, ISSN: 0036-8075 *
LECOUTER JENNIFER ET AL: "Identification of an angiogenic mitogen selective for endocrine gland endothelium", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 412, no. 6850, 30 August 2001 (2001-08-30), pages 877 - 884, XP002194811, ISSN: 0028-0836 *
SATO A K ET AL: "Development of mammalian serum albumin affinity purification media by peptide phage display", BIOTECHNOLOGY PROGRESS, XX, XX, vol. 18, no. 2, January 2002 (2002-01-01), pages 182 - 192, XP002348553, ISSN: 8756-7938 *
SHRIVASTAVA A ET AL: "A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS. SEP 2005, vol. 18, no. 9, September 2005 (2005-09-01), pages 417 - 424, XP002375785, ISSN: 1741-0126 *

Also Published As

Publication number Publication date
CA2666005A1 (en) 2003-09-12
EP2014310A2 (en) 2009-01-14
JP2009161549A (en) 2009-07-23
JP5039075B2 (en) 2012-10-03
EP2014310B8 (en) 2012-12-26
JP2006514915A (en) 2006-05-18
EP1572724A2 (en) 2005-09-14
EP2301587A3 (en) 2011-04-06
EP2301587A2 (en) 2011-03-30
SI2301587T1 (en) 2014-11-28
ES2398393T3 (en) 2013-03-15
EP2014310A3 (en) 2009-09-09
AU2009201114A1 (en) 2009-04-09
EP2301587B1 (en) 2014-06-25
ES2506142T3 (en) 2014-10-13
EP2014310B1 (en) 2012-10-24
CA2666005C (en) 2016-01-19
CA2477836A1 (en) 2003-09-12
WO2003074005A8 (en) 2005-07-21
WO2003074005A2 (en) 2003-09-12
AU2009201114B2 (en) 2012-01-19
AU2003213730A1 (en) 2003-09-16

Similar Documents

Publication Publication Date Title
DK1692158T3 (en) VEGF binding and supported peptides for the treatment of skin diseases
DE60325628D1 (en) Genes and polypeptides in connection with human pancreatic carcinomas
DK1487856T3 (en) KDR-specific human antibodies and their use
DE60043235D1 (en) Light-emitting particles and their use in diagnostics and therapy
EP1257217A4 (en) Apparatus for performing therapeutic procedures in the spine
AU2002363253A1 (en) Endothelial-cell binding peptides for diagnosis and therapy
PT2702871T (en) Collagen biofabric and use thereof
GB0324763D0 (en) Use of compounds in therapy
EP1751179A4 (en) Casein derived peptides and therapeutic uses thereof
EP1660122A4 (en) Immunostimulatory combinations and treatments
EG25613A (en) Thienopyrimidinediones and their use in the modulation of autoimmune disease
IL163563A (en) Anti-amyloid beta antibodies and their use in medicine
EP1765401A4 (en) Antibodies against human interleukin-13 and uses therefor
DE60239961D1 (en) Multiple component arrangement with improved binding characteristics for diagnosis and therapy
AP200704034A0 (en) Polypeptides sthat bind br3 and uses thereof
AU2003293376A8 (en) Anti-angiogenic compounds and their use in cancer treatment
HK1074991A1 (en) Cd16a binding proteins and use for the treatment of immune disorders cd16a
DK2336167T3 (en) MHC molecular constructs and their use in diagnosis and therapy
IL180725D0 (en) Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2003291609A1 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HK1074987A1 (en) Medical device package, kit and associated methods
EP1572723A4 (en) Skin or hair binding peptides
EP1804749A4 (en) Facial tissue strengthening and tightening device and methods
ZA200402846B (en) Human glucagon-like-peptide-1 mimics and their use in the treatmant of diabetes and related conditions.
IL173397D0 (en) Pyridyl derivatives and their use as therapeutic agents

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20041001

AK Designated contracting states:

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent to

Countries concerned: ALLTLVMK

A4 Despatch of supplementary search report

Effective date: 20060421

RA4 Despatch of supplementary search report

Effective date: 20070214

17Q First examination report

Effective date: 20071016

18D Deemed to be withdrawn

Effective date: 20090505